公开(公告)号：US20150011528A1

公开(公告)日：2015-01-08

申请号：US14346506

申请日：2012-09-21

申请人： YUHAN CORPORATION

发明人： Youn Hur ,  Dong-Hyun Kim ,  Eun-Kyung Kim ,  Jin-Hwi Park ,  Jae-Eun Joo ,  Ho-Woong Kang ,  Se-Woong Oh ,  Dong-Kyun Kim ,  Kyoung-Kyu Ahn

IPC分类号： C07D277/82 ,  C07D417/12 ,  C07D277/60 ,  C07D513/04

CPC分类号： C07D277/82 ,  C07D277/60 ,  C07D417/12 ,  C07D513/04

摘要： Provided is a phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the phenylimide-containing benzothiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

摘要翻译： 本发明提供含苯酰亚胺的苯并噻唑衍生物或其药学上可接受的盐，其制备方法和包含该方法的药物组合物。 含苯基酰亚胺的苯并噻唑衍生物或其药学上可接受的盐可以选择性地抑制KRS和层粘连蛋白受体（LR）之间的蛋白质 - 蛋白质相互作用，从而抑制癌细胞的迁移。 因此，含苯亚胺的苯并噻唑衍生物或其药学上可接受的盐可用于预防或治疗与癌细胞转移相关的疾病。

公开(公告)号：US20190142809A1

公开(公告)日：2019-05-16

申请号：US16315814

申请日：2017-07-06

申请人： Yuhan Corporation

发明人： Se-Woong Oh ,  Youn Hur ,  Jin-Hwi Park ,  Jae-Eun Joo ,  Ho-Woong Kang ,  Hyok-Jun Cho ,  Eui-Chul Lee ,  Chan-Sun Park ,  Dong-Hyun Kim ,  Jong-Gyun Kim ,  Su-Youn Nam

IPC分类号： A61K31/428 ,  A61P35/04

CPC分类号： A61K31/428 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61P35/04 ,  C07D277/82

摘要： The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

公开(公告)号：US11981659B2

公开(公告)日：2024-05-14

申请号：US17697655

申请日：2022-03-17

申请人： Yuhan Corporation

发明人： Sang Ho Oh ,  Jong Gyun Kim ,  Se-Woong Oh ,  Tae Dong Han ,  Soo Yong Chung ,  Seong Ran Lee ,  Kyeong Bae Kim ,  Young Sung Lee ,  Woo Seob Shin ,  Hyun Ju ,  Jeong Ki Kang ,  Su Min Park ,  Dong Kyun Kim

IPC分类号： C07D403/04 ,  C07C303/22 ,  C07C309/04

CPC分类号： C07D403/04 ,  C07C303/22 ,  C07C309/04 ,  C07B2200/13

摘要： The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.

公开(公告)号：US11453656B2

公开(公告)日：2022-09-27

申请号：US16605944

申请日：2018-04-18

申请人： Yuhan Corporation

发明人： Sang Ho Oh ,  Jong Gyun Kim ,  Se-Woong Oh ,  Tae Dong Han ,  Soo Yong Chung ,  Seong Ran Lee ,  Kyeong Bae Kim ,  Young Sung Lee ,  Woo Seob Shin ,  Hyun Ju ,  Jeong Ki Kang ,  Su Min Park ,  Dong Kyun Kim

IPC分类号： C07C309/04 ,  C07C303/22 ,  C07C403/04 ,  C07D403/04

摘要： The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yppyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.

公开(公告)号：US10383859B2

公开(公告)日：2019-08-20

申请号：US16315814

申请日：2017-07-06

申请人： Yuhan Corporation

发明人： Se-Woong Oh ,  Youn Hur ,  Jin-Hwi Park ,  Jae-Eun Joo ,  Ho-Woong Kang ,  Hyok-Jun Cho ,  Eui-Chul Lee ,  Chan-Sun Park ,  Dong-Hyun Kim ,  Jong-Gyun Kim ,  Su-Youn Nam

IPC分类号： C07D277/82 ,  A61K31/428 ,  A61P35/04

摘要： The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.